Already a member? Click here to login.
Already a member? Click here to login.
ADEA reminds its members to remind their clients that semaglutide products should be sourced from only trusted authorities amid the continued reports about counterfeit products putting consumers’ health at risk.
Recent media reports also state that regulators across the world have issued warnings in their crackdown of fake semaglutide, also known as Ozempic, being sold online.
The Therapeutic Goods Administration (TGA) issued a warning in May after it detected counterfeit semaglutide being illegally imported into Australia.
‘These results serve as a warning to consumers to avoid buying semaglutide products from unverified online sellers as they may not contain the active ingredient,’ the TGA said.
‘Counterfeit products may also contain other undeclared and hazardous ingredients that could cause serious risk to the health and safety of consumers.
‘They also may not meet manufacturing quality and safety standards and have unknown contaminants.’
The latest TGA advice was issued in September, urging prescribers to avoid starting new people on semaglutide ‘unless there are no suitable alternatives or there is a compelling clinical reason to do so’.
It came after supplier Novo Nordisk notified the TGA and the Ozempic Medicine Shortage Action Group that demand ‘had accelerated in recent months’.
More information at the TGA:
ADEA reminds its members to remind their clients that semaglutide products should be sourced from only trusted authorities amid the continued reports about counterfeit products putting consumers’ health at risk.
Recent media reports also state that regulators across the world have issued warnings in their crackdown of fake semaglutide, also known as Ozempic, being sold online.
The Therapeutic Goods Administration (TGA) issued a warning in May after it detected counterfeit semaglutide being illegally imported into Australia.
‘These results serve as a warning to consumers to avoid buying semaglutide products from unverified online sellers as they may not contain the active ingredient,’ the TGA said.
‘Counterfeit products may also contain other undeclared and hazardous ingredients that could cause serious risk to the health and safety of consumers.
‘They also may not meet manufacturing quality and safety standards and have unknown contaminants.’
The latest TGA advice was issued in September, urging prescribers to avoid starting new people on semaglutide ‘unless there are no suitable alternatives or there is a compelling clinical reason to do so’.
It came after supplier Novo Nordisk notified the TGA and the Ozempic Medicine Shortage Action Group that demand ‘had accelerated in recent months’.
More information at the TGA:
